METASTATIC SOLID TUMOR

This early-stage study tests a new drug called JZP898, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Abo…

This early-stage study tests a new drug, ADU-1805, in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with another cancer drug (pembrolizumab). The main goals are to check safety and how the body processes the drug. Abo…

This early-phase study tests a new drug called AGX101 in people with advanced solid tumors that have not responded to standard treatments. AGX101 is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find the safest dose and to check for sid…

This early-stage study tests an experimental pill called CID-078 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 220 adults with cancers like lung, breast…

This early-stage study tests a new drug (CHS-114) combined with an immunotherapy (toripalimab) in people with advanced or metastatic solid tumors that have not responded to prior treatments. The main goal is to check safety and see if the combination can shrink tumors. About 154 …

This study tests a new drug called NVL-655 in people with advanced ALK-positive lung cancer or other solid tumors. The goal is to find the best dose and see how well it shrinks tumors. About 840 adults will take part, and the drug is taken as a pill.

This early-phase study tests a new drug called XB628 in about 75 people with advanced solid tumors that have not responded to standard treatments. XB628 is designed to help the body's natural killer cells attack cancer cells more effectively. The main goals are to find a safe dos…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (like lung, head and neck, pancreatic, or kidney cancer). The drug is designed to help the immune system fight cancer by targeting a protein called CD73 and delivering a modified immune s…

This early-stage study tests an experimental drug called NVL-330 in people with advanced lung cancer that has specific changes in the HER2 gene. The main goals are to find a safe dose and see if the drug can shrink tumors. About 200 adults with this type of lung cancer will take …

This study is the first time the experimental drug KK2269 is being tested in people. It aims to check the safety of KK2269 given alone or with the chemotherapy drug docetaxel. The trial involves about 101 adults with advanced solid tumors (like stomach, lung, or esophageal cancer…

This early-phase study tests a new drug, CLSP-1025, designed to direct immune cells to attack tumors that have a specific p53 R175H mutation. The trial enrolls adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have worsened after standard treatments.…

This early-phase study tests a new drug called BGB-B2033, alone or with other cancer medicines, in people with advanced liver, stomach, lung, or rare germ cell tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Abo…

This early-phase study tests a new drug called tolododekin alfa (ANK-101) in people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various cancers, inclu…

This early-phase study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and can shrink tumors, either alone or with other cancer treatments. About 340 adults whose cancer has …

This study tests a new drug called zidesamtinib (NVL-520) in people with advanced lung cancer or other solid tumors that have a specific genetic change called ROS1. The goal is to find the best dose and see how well the drug shrinks tumors. About 359 adults will take part, and th…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This study tests whether combining two targeted drugs, pemigatinib and afatinib, is safe and works against advanced solid tumors that have certain FGFR gene changes. About 70 adults whose cancers have not responded to standard treatments will take part. The goal is to find the be…

This early-phase study tests a new drug called IL12-L19L19 in 80 adults with advanced or metastatic solid tumors that have not responded to standard immunotherapy. The main goal is to find a safe dose and check for early signs that the drug might shrink tumors. The drug is design…

This early-stage study tests a new drug called ASD141 in 21 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug moves through the body and…

This study tests an experimental drug called ART6043, taken as a pill, for people with advanced or metastatic solid tumors. The drug is given alone or with another cancer medicine (olaparib). The goal is to see if it is safe and can slow tumor growth. About 181 adults will take p…

This study tests a new experimental drug called GI-101, given alone or with other cancer drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with canc…

This study is for children and young adults with advanced or spreading solid tumors. It tests a new drug called repotrectinib combined with two chemotherapy drugs (irinotecan and temozolomide). The goal is to find the safest dose and see if the combination helps shrink tumors. Ab…

This early-phase study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic markers (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responde…

This study tests a new drug called IPN01203 in adults with advanced solid tumors that have spread and no longer respond to standard immune therapies. The goal is to find a safe and effective dose and see if the drug can slow or stop tumor growth. About 102 participants will recei…

This early-stage trial tests a combination of two drugs, niraparib and irinotecan, in people with advanced solid tumors that have mutations in DNA repair genes like BRCA, ATM, or PALB2. The main goal is to find a safe dose and understand side effects. About 24 adults with cancers…

This study tests an experimental drug called FMC-376 in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to find a safe dose and see if the drug can shrink tumors. About 400 adults whose cancer has worsened after standard treatments w…

This study tests whether two drugs, tucatinib and T-DM1, can control HER2-positive solid tumors that have spread to the brain. About 30 adults with this condition will receive the combination and be monitored for side effects and tumor response. The goal is to find a better treat…

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the safest and most effective dose and to see if the drug can shrink tumors. All participants receive the drug by injecti…

This study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…

This early-stage study is testing a new drug called SYN818 combined with olaparib in adults with advanced solid tumors (like ovarian or breast cancer) that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 110 part…

This study tests a new drug called DS-3939a in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose, and to see if the drug can shrink tumors. About 540 adults will take part across multiple centers.

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This early-phase study tests a new drug called BGB-B455 in people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find the safest dose and understand side effects. About 90 participants will join, and the study has two parts: f…

This early-phase study tests a new imaging drug (89Zr-DFO-REGN5054) that may help doctors see immune cells inside tumors using PET scans. About 50 adults with advanced solid cancers who are also receiving the immunotherapy cemiplimab will take part. The main goal is to check safe…

This study tests a new radiation technique called lattice radiation therapy (LRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better than standard radiation and whether it helps the immune system attack cancer cells. Abo…

This study tests whether a tretinoin cream can prevent or reduce the acne-like rash that often occurs as a side effect of certain cancer drugs (panitumumab or cetuximab). About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo to th…